查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020439

全球破傷風類毒素疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Tetanus Toxoid Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計破傷風類毒素疫苗市場將從 2025 年的 62.8 億美元成長到 2034 年的 107.1 億美元，2026 年至 2034 年的複合年成長率為 6.11%。

由於人們對疫苗接種的認知不斷提高，以及對破傷風預防重要性的理解不斷加深，全球破傷風類毒素疫苗市場正穩定成長。破傷風是嚴重的細菌性疾病，可透過接種疫苗預防，破傷風類毒素疫苗是國家免疫計畫的重要組成部分。政府措施和全球衛生宣傳活動在提高疫苗接種率方面發揮著至關重要的作用。

發展中地區醫療保健投資的增加和免疫接種服務可近性的提高是市場成長的主要驅動力。國際組織和公共衛生組織正致力於擴大免疫接種計劃，尤其是在農村地區和醫療保健資源匱乏的地區。破傷風疫苗納入兒童和孕產婦常規免疫接種計畫進一步刺激了市場需求。

隨著全球免疫接種工作的持續推進，破傷風類毒素疫苗市場預計將持續成長。疫苗儲存、分發和聯合疫苗技術的進步將提高疫苗的可及性和接種率。隨著醫療衛生系統將重點轉向預防醫學和疾病控制，全球對破傷風疫苗的需求預計將保持強勁。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球破傷風類毒素疫苗市場：依疫苗類型分類

  • 市場分析、洞察與預測
  • 破傷風類毒素（Tt）
  • 白喉和破傷風（Dt）
  • 破傷風和白喉（Td）
  • 白喉、破傷風、百日咳（DTaP）
  • 破傷風、白喉、百日咳（Tdap）
  • 白喉、破傷風、百日咳、b型流感嗜血桿菌、B型肝炎（DTP-Hib-HepB）
  • 五價疫苗（DTaP-IPV/Hib）
  • 六價疫苗（DTaP-IPV/Hib-HepB）
  • 其他疫苗類型

第5章：全球破傷風類毒素疫苗市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第6章：全球破傷風類毒素疫苗市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 政府機構
  • 其他最終用戶

第7章 全球破傷風類毒素疫苗市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Bharat Biotech International Limited
    • Biological E. Limited
    • Biological Products Institute（BPI）Argentina
    • Chengdu Institute Of Biological Products Co. Ltd
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck & Co. Inc
    • Mitsubishi Tanabe Pharma Corporation
    • Panacea Biotec
    • Pfizer Inc
    • Sanofi
    • Serum Institute Of India
    • Zydus Group
簡介目錄
Product Code: VMR112113431

The Tetanus Toxoid Vaccine Market size is expected to reach USD 10.71 Billion in 2034 from USD 6.28 Billion (2025) growing at a CAGR of 6.11% during 2026-2034.

The global tetanus toxoid vaccine market is growing steadily due to increasing awareness about immunization and the importance of preventing tetanus infections. Tetanus is a serious bacterial disease that can be prevented through vaccination, making tetanus toxoid vaccines a critical component of national immunization programs. Government initiatives and global health campaigns are playing a significant role in promoting vaccine coverage.

Rising healthcare investments and improved access to vaccination services in developing regions are key factors driving market growth. International organizations and public health agencies are working to expand immunization programs, particularly in rural and underserved areas. The inclusion of tetanus vaccines in routine childhood and maternal vaccination schedules is further supporting demand.

In the future, the tetanus toxoid vaccine market is expected to grow as global immunization efforts continue to expand. Advances in vaccine storage, distribution, and combination vaccines will improve accessibility and coverage. As healthcare systems focus on preventive care and disease control, the demand for tetanus vaccines is likely to remain strong worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Vaccine Type

  • Tetanus Toxoid (Tt)
  • Diphtheria And Tetanus (Dt)
  • Tetanus And Diphtheria (Td)
  • Diphtheria, Tetanus, And Pertussis (Dtap)
  • Tetanus, Diphtheria, And Pertussis (Tdap)
  • Diphtheria, Tetanus, Pertussis, Hib And Hepatitis B (Dtp-Hib-Hepb)
  • Pentavalent (Dtap-Ipv/Hib)
  • Hexavalent (Dtap-Ipv/Hib-Hepb)
  • Other Vaccine Types

By Age Group

  • Pediatric
  • Adult

By End-Use

  • Hospitals And Clinics
  • Government Organizations
  • Other End-Users

COMPANIES PROFILED

  • Bharat Biotech International Limited, Biological E Limited, Biological Products Institute BPI Argentina, Chengdu Institute of Biological Products Co Ltd, GlaxoSmithKline, Johnson Johnson, Merck Co Inc, Mitsubishi Tanabe Pharma Corporation, Panacea Biotec, Pfizer Inc, Sanofi, Serum Institute of India, Zydus Group
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL TETANUS TOXOID VACCINE MARKET: BY VACCINE TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Vaccine Type
  • 4.2. Tetanus Toxoid (Tt) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Diphtheria And Tetanus (Dt) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Tetanus And Diphtheria (Td) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.5. Diphtheria, Tetanus, And Pertussis (Dtap) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.6. Tetanus, Diphtheria, And Pertussis (Tdap) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.7. Diphtheria, Tetanus, Pertussis, Hib And Hepatitis B (Dtp-Hib-Hepb) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.8. Pentavalent (Dtap-Ipv/Hib) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.9. Hexavalent (Dtap-Ipv/Hib-Hepb) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.10. Other Vaccine Types Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL TETANUS TOXOID VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Age Group
  • 5.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL TETANUS TOXOID VACCINE MARKET: BY END-USE 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast End-use
  • 6.2. Hospitals And Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Government Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.4. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL TETANUS TOXOID VACCINE MARKET: BY REGION 2022-2034 (USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Vaccine Type
    • 7.2.2 By Age Group
    • 7.2.3 By End-use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Vaccine Type
    • 7.3.2 By Age Group
    • 7.3.3 By End-use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Vaccine Type
    • 7.4.2 By Age Group
    • 7.4.3 By End-use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Vaccine Type
    • 7.5.2 By Age Group
    • 7.5.3 By End-use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Vaccine Type
    • 7.6.2 By Age Group
    • 7.6.3 By End-use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TETANUS TOXOID VACCINE INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Bharat Biotech International Limited
    • 9.2.2 Biological E. Limited
    • 9.2.3 Biological Products Institute (BPI) Argentina
    • 9.2.4 Chengdu Institute Of Biological Products Co. Ltd
    • 9.2.5 GlaxoSmithKline
    • 9.2.6 Johnson & Johnson
    • 9.2.7 Merck & Co. Inc
    • 9.2.8 Mitsubishi Tanabe Pharma Corporation
    • 9.2.9 Panacea Biotec
    • 9.2.10 Pfizer Inc
    • 9.2.11 Sanofi
    • 9.2.12 Serum Institute Of India
    • 9.2.13 Zydus Group